Roche Holding AG/€ROG

05:30
08:40
11:45
14:55
18:00
1D1W1MYTD1Y5YMAX

About Roche Holding AG

Roche Holding AG is a Swiss multinational healthcare company based in Basel, Switzerland, specializing in pharmaceuticals and diagnostics. The company's pharmaceutical division is renowned for developing innovative medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Roche's diagnostics segment offers products and services for research and medical applications, including in vitro diagnostics and instruments for hospitals, labs, and physicians. Founded in 1896, Roche has a significant global presence, operating in numerous countries worldwide. The company is strategically positioned through its focus on personalized healthcare, leveraging its expertise in both pharmaceuticals and diagnostics to deliver tailored treatment solutions.

Ticker

€ROG
Sector

Primary listing

XGAT

Employees

103,249

Headquarters

Basel, Switzerland

Roche Holding AG Metrics

BasicAdvanced
€264B
24.47
€12.57
0.17
€10.14
3.29%

Bulls say / Bears say

Roche beat H1 2025 operating profit forecasts with a 6 % rise to CHF 12 billion (11 % CER), driven by Phesgo sales up 55 % to CHF 1.2 billion and Xolair up 34 % to CHF 1.45 billion, demonstrating strong execution in key therapeutic franchises (Reuters).
Roche plans to launch a late-stage trial investigating its BrainShuttle antibody trontinemab for Alzheimer’s prevention or delay, leveraging novel CNS delivery technology to target a high-unmet-need market and complement diagnostics capabilities (Reuters).
Roche’s commitment to invest USD 50 billion in U.S. R&D and manufacturing over five years will create over 12,000 jobs and bolster U.S. supply chain resilience, positioning the company favorably amid potential tariff risks and strengthening its largest market presence (Reuters).
Diagnostics division revenue remained flat at CHF 7 billion in H1 2025, with gains in pathology solutions offset by pricing reforms in China, highlighting limited growth diversification in non-pharma segments (Reuters).
Roche’s Phase III MUSETTE trial of a higher-dose formulation of its MS drug Ocrevus failed to meet its primary endpoint, curbing prospects for expanding usage and extending the product’s lifecycle beyond the standard 600 mg dose (Reuters).
In Alzheimer’s research, Roche’s trontinemab faces intensified competition as Eli Lilly’s Kisunla received an EMA recommendation and Biogen/Eisai’s Leqembi remains established, potentially limiting Roche’s market share in a crowded field (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy €ROG

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs